Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The gut microbiota modulates responses to anti–PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors

25 Oct 2022

Abstract excerpt

Background Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) have been widely used in treating different malignancies. Several studies have reported that the gut microbiota modulates the response and adverse events (AEs) to ICIs in melanoma, non–small cell lung cancer (NSCLC), renal cell cancer and hepatocellular carcinoma, but data on other cancer types and ICI combination...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to Gut microbiota and health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36387171
DOI: 10.3389/fonc.2022.887383

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The gut microbiota modulates responses to anti–PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumorsPMID 36387171Read ↗

A review on the role of gut microbiota in immune checkpoint blockade therapy for cancerSemantic proximity Read ↗

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockadeSemantic proximity Read ↗

Complex interactions between the microbiome and cancer immune therapySemantic proximity Read ↗

Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivorsSemantic proximity Read ↗

Microbiome landscape and association with response to immune checkpoint inhibitors in advanced solid tumors: SCRUM-Japan MONSTAR-SCREENSemantic proximity Read ↗

The intimate relationship between gut microbiota and cancer immunotherapySemantic proximity Read ↗

Gut microbiota as a prognostic biomarker for unresectable hepatocellular carcinoma treated with anti-PD-1 therapySemantic proximity Read ↗

Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomesSemantic proximity Read ↗

Catalog of gut microbiota alterations associated with anticancer therapies across multiple cancer typesSemantic proximity Read ↗

Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor/ligand targeted cancer immunotherapySemantic proximity Read ↗

Gut Microbiota Shifts from Onset to Remission in Immune Checkpoint Inhibitor-Induced Enterocolitis: A Case ReportSemantic proximity Read ↗

The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.